Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $94,035,000 | $72,044,000 | $72,984,000 | $76,034,000 |
| % Growth | 30.5% | -1.3% | -4% | – |
| Cost of Goods Sold | $35,502,000 | $33,505,000 | $33,428,000 | $34,458,000 |
| Gross Profit | $58,532,000 | $38,539,000 | $39,556,000 | $41,576,000 |
| % Margin | 62.2% | 53.5% | 54.2% | 54.7% |
| R&D Expenses | $18,725,000 | $12,543,000 | $15,789,000 | $8,420,000 |
| G&A Expenses | $0 | $31,000 | $0 | $0 |
| SG&A Expenses | $18,501,000 | $16,165,000 | $15,476,000 | $15,833,000 |
| Sales & Mktg Exp. | $0 | $16,134,000 | $0 | $0 |
| Other Operating Expenses | $273,000 | $318,000 | $334,000 | $130,000 |
| Operating Expenses | $37,499,000 | $29,026,000 | $31,553,000 | $24,508,000 |
| Operating Income | $21,034,000 | $9,513,000 | $7,998,000 | $17,064,000 |
| % Margin | 22.4% | 13.2% | 11% | 22.4% |
| Other Income/Exp. Net | -$1,599,000 | $283,000 | -$1,181,000 | -$3,179,000 |
| Pre-Tax Income | $19,435,000 | $9,796,000 | $6,817,000 | $13,885,000 |
| Tax Expense | $5,490,000 | $1,770,000 | $1,377,000 | $4,336,000 |
| Net Income | $13,945,000 | $8,025,000 | $5,440,000 | $9,549,000 |
| % Margin | 14.8% | 11.1% | 7.5% | 12.6% |
| EPS | 365.42 | 212.66 | 144.79 | 251.44 |
| % Growth | 71.8% | 46.9% | -42.4% | – |
| EPS Diluted | 365.42 | 212.66 | 144.79 | 251.44 |
| Weighted Avg Shares Out | 38,162 | 37,737 | 37,571 | 37,978 |
| Weighted Avg Shares Out Dil | 38,162 | 37,737 | 37,571 | 37,978 |
| Supplemental Information | – | – | – | – |
| Interest Income | $77,000 | $8,000 | $7,000 | $6,000 |
| Interest Expense | $28,000 | $17,000 | $17,000 | $17,000 |
| Depreciation & Amortization | $2,554,000 | $2,753,000 | $2,568,000 | $2,481,000 |
| EBITDA | $22,017,000 | $12,566,000 | $9,402,000 | $16,384,000 |
| % Margin | 23.4% | 17.4% | 12.9% | 21.5% |